Currently, male infertility accounts for about 30-40% of the 10% of infertile couples in the fertile age population and is increasing by 5% per year. Although the exact cause of male infertility cannot be determined in most cases, many patients can be treated to produce blood relatives. 1, for the treatment of non-congenital vas deferens obstructive azoospermia patients, the first choice is still the vas deferens or vas deferens epididymal microscopic anastomosis, which is also the direction of the treatment of such azoospermia patients in the future. However, with the development of microsurgery and the increasing maturity of microscopic techniques, experienced and skilled microsurgeons can achieve a positive sperm test rate of up to 80% after vasoepididymitis anastomosis, and a natural pregnancy rate of up to 40% for their wives. Compared with IVF, the higher success rate and lower medical cost have put a pair of beautiful wings for such azoospermia patients to realize their dream of having children. 2. There is also a new view on the treatment of azoospermia patients. It is well known that hormones play an important role in the process of sperm development and maturation, especially growth hormone, which has been used in the treatment of male infertility. At the same time, we should also pay attention to the fact that in the process of drug treatment, patients may have gonadal function decline at any time, which may lead to no sperm, so Qiangliu suggests us to do fertility preservation (sperm cryopreservation) first in the process of drug treatment for patients with severe oligozoospermia. 3.Pluripotent stem cells bring hope to people in vitro culture induced differentiation of spermatozoa, but due to the small content in germ cells and its specific labeling has not been fully confirmed at present, so the research of pluripotent stem cells is still in experimental stage. In any case, it has after all opened a door of hope for patients with spermatogenic disorders.